Psychedelics-focused biotech Compass Pathways has signed a research collaboration with New Jersey’s Hackensack Meridian Health regarding the delivery model design of its investigational COMP360 psilocybin treatment.
In late December, Compass reported phase 2 safety data from the first clinical trial of psilocybin in post-traumatic stress disorder (PTSD). That news came fast on the heels of the Multidisciplinary Association for Psychedelic Studies’ (MAPS) application to the FDA for MDMA, marking the first new drug submission of a psychedelic-assisted therapy for PTSD.
Long associated with counter-culture use, psilocybin is the psychoactive ingredient in magic mushrooms that produces hallucinogenic effects. Compass, MAPS and others have been evaluating the safety and tolerability of psilocybin in patients with PTSD for several years.
Read more